Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JESS14 interval-compressed VDC-IE for localized Ewing sarcoma family tumor
jRCTs021180022Phase 2Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Feb 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide and 1 more in Ewing family of tumors (EFT), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: 3-year progression-free survival. Started Feb 2016; status: recruiting.
02
Drugs
cyclophosphamidedoxorubicinvincristineifosfamideetoposide
03
Conditions
Ewing family of tumors (EFT)
Beyond the preview
Go deeper on jRCTs021180022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021180022.